{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:22:00Z","timestamp":1783606920371,"version":"3.55.0"},"reference-count":39,"publisher":"Bioscientifica","issue":"6","content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,6,1]]},"abstract":"<jats:p>Small bowel neuroendocrine tumors represent a rare malignancy, and most patients present with metastatic disease at diagnosis. While current guidelines from the North American Neuroendocrine Tumor Society and the European Neuroendocrine Tumor Society agree that resection is indicated for symptomatic tumors causing obstruction, ischemia, or bleeding, the role of primary tumor resection in otherwise asymptomatic patients with unresectable metastatic disease remains controversial. This article reviews the existing evidence and highlights the role of primary tumor resection in the setting of metastatic disease. Retrospective studies support mixed findings: some boast a survival advantage for patients undergoing resection of the primary tumor, while others caution that other prognostic factors, including those related to tumor biology, are the true drivers of this benefit. However, it is known that many patients are not truly asymptomatic if a thorough history and physical is performed, and symptom burden can become significant over time. Upfront resection of the primary small bowel tumor prevents development of local complications, such as bowel obstruction or mesenteric vascular compromise, which may require emergency surgery. It has been shown that patients who underwent surgery in the emergent setting (as opposed to elective) had worse survival outcomes and tended to have more incomplete tumor resection and a significantly smaller lymph node yield. Nonetheless, the absence of prospective or randomized controlled studies leaves the value of primary tumor resection unproven, underscoring the critical need for well-designed trials incorporating quality-of-life metrics and obstruction-free survival as key patient-centered outcomes.<\/jats:p>","DOI":"10.1530\/erc-25-0477","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T10:25:08Z","timestamp":1780914308000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":0,"title":["Primary tumor resection in the setting of unresectable metastatic disease in small bowel NETs: consensus and controversy"],"prefix":"10.1530","volume":"33","author":[{"given":"Emilie AK","family":"Warren","sequence":"first","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline D","family":"Roorbach","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Ernyey","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9638-3629","authenticated-orcid":true,"given":"Udhayvir S","family":"Grewal","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Gangi","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel M","family":"Halperin","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3918-3954","authenticated-orcid":true,"given":"Seth","family":"Concors","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"2026070909473067600_bib1","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2025.15798","article-title":"Epidemiology of neuroendocrine neoplasms in the US","volume":"8","author":"Dasari","year":"2025","journal-title":"JAMA Netw Open"},{"key":"2026070909473067600_bib2","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s11605-017-3586-8","article-title":"Multifocality in small bowel neuroendocrine tumors","volume":"22","author":"Gangi","year":"2018","journal-title":"J Gastrointest Surg"},{"key":"2026070909473067600_bib3","article-title":"DOTATATE PET CT tumor volume as a predictor of surgical outcome in patients with metastatic gastroenteropancreatic neuroendocrine tumors","volume":"2","author":"Abou Azar","year":"2025","journal-title":"Surg Oncol Insight"},{"key":"2026070909473067600_bib4","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/SLA.0b013e31818e4641","article-title":"Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years","volume":"249","author":"Bilimoria","year":"2009","journal-title":"Ann Surg"},{"key":"2026070909473067600_bib5","doi-asserted-by":"crossref","first-page":"869","DOI":"10.21037\/jgo.2019.05.02","article-title":"Survival trends of metastatic small intestinal neuroendocrine tumor: a population-based analysis of SEER database","volume":"10","author":"Shah","year":"2019","journal-title":"J Gastrointest Oncol"},{"key":"2026070909473067600_bib6","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/17446651.2023.2237593","article-title":"Understanding the increasing incidence of neuroendocrine tumors","volume":"18","author":"Pathak","year":"2023","journal-title":"Expert Rev Endocrinol Metab"},{"key":"2026070909473067600_bib7","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/MPA.0000000000000846","article-title":"The surgical management of small bowel neuroendocrine tumors","volume":"46","author":"Howe","year":"2017","journal-title":"Pancreas"},{"key":"2026070909473067600_bib8","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.surg.2015.05.040","article-title":"Liver-directed surgery of neuroendocrine metastases: what is the optimal strategy?","volume":"159","author":"Maxwell","year":"2016","journal-title":"Surg"},{"key":"2026070909473067600_bib9","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1245\/s10434-023-14610-0","article-title":"Surgery as a principle and technical consideration for primary tumor resection of small bowel neuroendocrine tumors","volume":"31","author":"S\u00f8reide","year":"2024","journal-title":"Ann Surg Oncol"},{"key":"2026070909473067600_bib10","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13423","article-title":"European Neuroendocrine Tumor Society (ENETS) 2024 guidance paper for the management of well-differentiated small intestine neuroendocrine tumours","volume":"36","author":"Lamarca","year":"2024","journal-title":"J Neuroendocrinol"},{"key":"2026070909473067600_bib11","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1007\/s002680010232","article-title":"Method for dissection of mesenteric metastases in mid-gut carcinoid tumors","volume":"24","author":"\u00d6hrvall","year":"2000","journal-title":"World J Surg"},{"key":"2026070909473067600_bib12","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.3390\/cancers14153610","article-title":"Vessel-sparing lymphadenectomy should be performed in small intestine neuroendocrine neoplasms","volume":"14","author":"Bartsch","year":"2022","journal-title":"Cancers"},{"key":"2026070909473067600_bib13","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00268-020-05727-4","article-title":"Role of primary tumor resection for metastatic small bowel neuroendocrine tumors","volume":"45","author":"Hallet","year":"2021","journal-title":"World J Surg"},{"key":"2026070909473067600_bib14","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.hoc.2015.09.001","article-title":"Surgical treatment of small bowel neuroendocrine tumors","volume":"30","author":"Farley","year":"2016","journal-title":"Hematol Oncol Clin North Am"},{"key":"2026070909473067600_bib15","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1530\/ERC-17-0282","article-title":"Mesenteric fibrosis and palliative surgery in small intestinal neuroendocrine tumours","volume":"25","author":"Bla\u017eevi\u0107","year":"2018","journal-title":"Endocr Relat Cancer"},{"key":"2026070909473067600_bib16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1001\/jamaoncol.2017.3326","article-title":"Association of a prophylactic surgical approach to stage IV small intestinal neuroendocrine tumors with survival","volume":"4","author":"Daskalakis","year":"2018","journal-title":"JAMA Oncol"},{"key":"2026070909473067600_bib17","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.surg.2006.07.033","article-title":"Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival","volume":"140","author":"Givi","year":"2006","journal-title":"Surgery"},{"key":"2026070909473067600_bib18","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1677\/ERC-09-0042","article-title":"Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study","volume":"16","author":"Ahmed","year":"2009","journal-title":"Endocr Relat Cancer"},{"key":"2026070909473067600_bib19","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13399","article-title":"Impact of primary tumor resection in the management of metastatic well-differentiated neuroendocrine tumors of the small bowel and pancreas","volume":"36","author":"Russo","year":"2024","journal-title":"J Neuroendocrinol"},{"key":"2026070909473067600_bib20","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.surg.2018.09.006","article-title":"Resection of primary tumor may prolong survival in metastatic gastroenteropancreatic neuroendocrine tumors","volume":"165","author":"Tierney","year":"2019","journal-title":"Surgery"},{"key":"2026070909473067600_bib21","doi-asserted-by":"crossref","first-page":"4525","DOI":"10.1245\/s10434-020-08510-w","article-title":"Midgut neuroendocrine tumors with liver-only metastases: benefit of primary tumor resection","volume":"27","author":"Gangi","year":"2020","journal-title":"Ann Surg Oncol"},{"key":"2026070909473067600_bib22","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1007\/s11605-018-04094-9","article-title":"Is resection of primary midgut neuroendocrine tumors in patients with unresectable metastatic liver disease justified? A systematic review and meta-analysis","volume":"23","author":"Tsilimigras","year":"2019","journal-title":"J Gastrointest Surg"},{"key":"2026070909473067600_bib23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1093\/bjs\/znab413","article-title":"Effect of primary tumour resection without curative intent in patients with metastatic neuroendocrine tumours of the small intestine and right colon: meta-analysis","volume":"109","author":"Van Den Heede","year":"2022","journal-title":"Br J Surg"},{"key":"2026070909473067600_bib24","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000443612","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide lar in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors (PROMID): results of long-term survival","volume":"104","author":"Rinke","year":"2016","journal-title":"Neuroendocrinology"},{"key":"2026070909473067600_bib25","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"2026070909473067600_bib26","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"2026070909473067600_bib27","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa2403991","article-title":"Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors","volume":"392","author":"Chan","year":"2025","journal-title":"N Engl J Med"},{"key":"2026070909473067600_bib28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 trial of 177 Lu-Dotatate for midgut neuroendocrine tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N Engl J Med"},{"key":"2026070909473067600_bib29","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1007\/s002689900137","article-title":"Progression of metastases and symptom improvement from laparotomy in midgut carcinoid tumors","volume":"20","author":"Makridis","year":"1996","journal-title":"World J Surg"},{"key":"2026070909473067600_bib30","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1007\/s00268-002-6630-z","article-title":"Effect of surgery on the outcome of midgut carcinoid disease with lymph node and liver metastases","volume":"26","author":"Hellman","year":"2002","journal-title":"World J Surg"},{"key":"2026070909473067600_bib31","doi-asserted-by":"crossref","first-page":"2711","DOI":"10.1245\/s10434-019-07441-5","article-title":"Symptom burden at the end of life for neuroendocrine tumors: an analysis of 2579 prospectively collected patient-reported outcomes","volume":"26","author":"Hallet","year":"2019","journal-title":"Ann Surg Oncol"},{"key":"2026070909473067600_bib32","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s11154-018-9469-9","article-title":"Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract","volume":"19","author":"Goretzki","year":"2018","journal-title":"Rev Endocr Metab Disord"},{"key":"2026070909473067600_bib33","first-page":"5","article-title":"Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care","volume":"30","author":"Rivero","year":"2023","journal-title":"Endocr Relat Cancer"},{"key":"2026070909473067600_bib34","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/14574969241271841","article-title":"Emergency surgery influences oncological outcome in small intestinal neuroendocrine tumors","volume":"113","author":"Butz","year":"2024","journal-title":"Scand J Surg"},{"key":"2026070909473067600_bib35","doi-asserted-by":"crossref","first-page":"E450","DOI":"10.1097\/SLA.0000000000004647","article-title":"Upfront small bowel resection for small bowel neuroendocrine tumors with synchronous metastases: a propensity-score matched comparative population-based analysis","volume":"276","author":"Bennett","year":"2022","journal-title":"Ann Surg"},{"key":"2026070909473067600_bib36","article-title":"Risk of bowel ischemia in patients with mesenteric neuroendocrine tumors after treatment with 177Lu-DOTATATE","volume":"5","author":"Pelle","year":"2025","journal-title":"Endocr Oncol"},{"key":"2026070909473067600_bib37","article-title":"Case series: abscopal benefit of surgery in 3 immunotherapy-treated patients with unresectable cancer","volume":"6","author":"Oronsky","year":"2018","journal-title":"J Investig Med High Impact Case Rep"},{"key":"2026070909473067600_bib38","first-page":"8","article-title":"A review of the abscopal effect in the era of immunotherapy","volume":"96","author":"Nabrinsky","year":"2022","journal-title":"Cureus"},{"key":"2026070909473067600_bib39","article-title":"Surgical management of small intestinal neuroendocrine tumours","volume":"113","author":"Hallet","year":"2026","journal-title":"BJS"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/33\/6\/ERC-25-0477.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/33\/6\/ERC-25-0477.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0477\/519865\/erc-25-0477.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article-pdf\/doi\/10.1530\/ERC-25-0477\/519865\/erc-25-0477.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:47:44Z","timestamp":1783604864000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/erc\/article\/33\/6\/e250477\/77562\/Primary-tumor-resection-in-the-setting-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,1]]},"references-count":39,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,1]]}},"URL":"https:\/\/doi.org\/10.1530\/erc-25-0477","relation":{},"ISSN":["1479-6821","1351-0088"],"issn-type":[{"value":"1479-6821","type":"electronic"},{"value":"1351-0088","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,1]]},"article-number":"e250477"}}